Rigel Pharmaceuticals, Inc. (RIGL) Stock Forecast
RIGL analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.20 / 5 from 5 analysts
- Price target
- $63.00 average of analyst targets
- Upside to target
- +37.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.87
- 52-week range
- $25.44 – $50.96
RIGL analyst ratings
5 analystsNumber of analysts at each rating.
RIGL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RIGL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.96 | $0.77 | $1.07 | $1.46 | −34.0% | 4 |
| Current fiscal year (2026) | $3.54 | $2.55 | $4.61 | $6.43 | −44.9% | 4 |
| Next fiscal year (2027) | $4.94 | $2.87 | $7.32 | $3.54 | +39.4% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RIGL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $80.1M | $75.1M | $83.2M | +15.3% | 5 |
| Current fiscal year (2026) | $305.7M | $294.1M | $318.3M | +3.9% | 5 |
| Next fiscal year (2027) | $372.8M | $330.0M | $407.4M | +21.9% | 5 |
RIGL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RIGL revenue: reported and forecast
RIGL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.27 | $1.22 | $0.89 | $0.96 | $0.96 | −24.4% | 0 up · 4 down |
| Current fiscal year (2026) | $3.09 | $2.92 | $3.43 | $3.54 | $3.54 | +14.7% | 1 up · 3 down |
| Next fiscal year (2027) | $4.58 | $4.78 | $4.39 | $4.94 | $4.94 | +7.8% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RIGL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RIGL beat in 8 of 12.
What analysts expect from RIGL
5 analysts cover Rigel Pharmaceuticals; their consensus rating is buy (4.20 on a 1–5 scale, where 5 is a strong buy). The average price target is $63.00, 37.0% above the latest close of $45.97. Analysts expect earnings of $3.54 per share for 2026, −44.9% from a year earlier. For 2027 the average estimate is $4.94 per share on revenue of $372.8 million. Rigel Pharmaceuticals beat the EPS estimate in 8 of the last 12 quarters.
Related: RIGL income statement, RIGL key metrics, RIGL chart. See the RIGL stock overview for the latest quote and news.
RIGL forecast FAQ
What is Rigel Pharmaceuticals's price target?
The average analyst price target for Rigel Pharmaceuticals is $63.00, 37.0% above the latest close of $45.97.
Is Rigel Pharmaceuticals a buy, hold or sell?
Of 5 analysts covering Rigel Pharmaceuticals, 3 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Rigel Pharmaceuticals's EPS forecast?
Analysts forecast $3.54 per share for 2026 (range $2.55 to $4.61); for 2027 the estimate is $4.94.
What is Rigel Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $305.7 million, growth of 3.9%; for 2027 it is $372.8 million.
When does Rigel Pharmaceuticals report earnings?
Rigel Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $0.87.
Does Rigel Pharmaceuticals usually beat earnings estimates?
Rigel Pharmaceuticals reported EPS at or above the analyst estimate in 8 of the last 12 quarters.